In addition, DNA-PK inhibitors significantly enhanced the secretion of TGF-β in the tumor microenvironment and the expression of PD-L1 in irradiated cancer cells, providing a theoretical basis for the combination of DNA-PK inhibitors with immunotherapy. The gene discussed is CD274; the disease is neoplasm.